



Cite this: *Med. Chem. Commun.*, 2018, 9, 383

DOI: 10.1039/c8md90005a  
[rsc.li/medchemcomm](http://rsc.li/medchemcomm)

## Correction: Synthesis, characterization and biological application of 5-quinoline 1,3,5-trisubstituted pyrazole based platinum(II) complexes

Miral V. Lunagariya,<sup>a</sup> Khyati P. Thakor,<sup>a</sup> Reena R. Varma,<sup>a</sup> Bhargav N. Waghela,<sup>b</sup> Chandramani Pathak <sup>b</sup> and Mohan N. Patel <sup>\*a</sup>

Correction for 'Synthesis, characterization and biological application of 5-quinoline 1,3,5-trisubstituted pyrazole based platinum(II) complexes' by Miral V. Lunagariya *et al.*, *MedChemComm*, 2018, DOI: 10.1039/c7md00472a.


The authors regret that ligands  $L^1$ – $L^5$  are not named correctly in the manuscript. The names are missing '4,5-dihydro' as displayed in the experimental section. The correct names are as follows: 2-chloro-3-(3-(5-chlorothiophen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-5-yl)quinoline ( $L^1$ ), 2-chloro-3-(3-(4-methylthiophen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-5-yl)quinoline ( $L^2$ ), 3-(3-(5-bromothiophen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-5-yl)-2-chloroquinoline ( $L^3$ ), 3-(3-(3-bromothiophen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-5-yl)-2-chloroquinoline ( $L^4$ ) and 2-chloro-3-(1-phenyl-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)quinoline ( $L^5$ ).

Scheme 1, with corrected name for  $L^1$ – $L^5$ , is shown below.



<sup>a</sup> Department of Chemistry, Sardar Patel University, Vallabh Vidyanagar-388 120, Gujarat, India. E-mail: [jeenen@gmail.com](mailto:jeenen@gmail.com); Tel: +912692 226856 218

<sup>b</sup> Department of Cell Biology, School of Biological Sciences and Biotechnology, Indian Institute of Advanced Research, Koba Institutional Area, Gandhinagar-382007, Gujarat, India. Tel: +91 79 30514245



Scheme 1

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

